Accelerating the development of life-saving treatments.
Machine-generated by The Flow from the publisher's headline and feed description — not written or checked by a human. The full article lives at OpenAI Blog.
Stanford geneticist uses Co-Scientist to help find new treatments for chronic liver disease and liver fibrosis.
Discover how a specialized AI model, GPT-4b micro, helped OpenAI and Retro Bio engineer more effective proteins for stem cell therapy and longevity research.
arXiv:2609.21859v1 Announce Type: new Abstract: Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely o...
The study examined biomedical research articles from 2022 to March 2026 that employed large language models (LLMs). It found that 42% of the most frequently used models were already retired or scheduled to retire within two years of publication, with a median retirement interval of 538 days. This high rate of model deprecation threatens the reproducibility of biomedical AI research.
GPT-Rosalind advances life sciences research with enhanced biological reasoning, medicinal chemistry expertise, genomics analysis, and experimental workflow capabilities.
OpenAI introduces GPT-Rosalind, a frontier reasoning model built to accelerate drug discovery, genomics analysis, protein reasoning, and scientific research workflows.
